Diabetes		Insulin glulisine
Blood Sugar; Diabetes Mellitus; Non-Insulin Dependent Diabetes Mellitus; Type II Diabetes		Apidra; Insulin Glulisine [recombinant DNA origin]

Pictures

figure7 png

profiles after subcutaneous injection of insulin aspart insulin lispro insulin glulisine regular insulin NPH insulin insulin detemir and insulin glargine

---

figure8 png

The rapid acting analogues only provide prandial insulin while regular insulin contributes to both prandial and basal insulinemia B=breakfast L=lunch

---

figure9 png

is still active and provides the patient a final suggested dose which the patient may activate or override B=breakfast L=lunch S=supper HS=bedtime

---

apidra chem gif

duration Apidra 6 may be diluted for all uses except in insulin pumps It may be mixed in the same syringe with NPH isophane insulin only http products sanofi aventis us apidra images apidra chem gif Alterations to human insulin producing insulin glulisine Apidra There is no clinical data regarding same syringe mixing of

---

apidra claim gif

---

aboutapidra jpg

About Apidra ® Flexible Rapid Acting Insulin

---

766 SANOFI AVENTIS

---

31001601 jpg

In a euglycemic clamp study in patients with type 2 diabetes n=24 with a body mass index BMI between 20 to 36 kg m 2 after subcutaneous administration of 0 2 IU kg the

---

apidra image02 jpg

Figure 1 Figure 1 Pharmacokinetic profiles of insulin glulisine and regular human insulin in patients with type 1 diabetes after a dose of 0 15 IU kg In a euglycemic clamp study in patients with type 2 diabetes n=24 with a body mass index BMI between 20 to 36 kg m2 after subcutaneous administration of 0 2 IU kg the median time to

---

DisplayImage asp

minutes and a Cmax of 46 ± 1 3 μ U ml for regular human insulin The mean residence time of insulin glulisine was shorter 98 min than for regular human insulin 161 min see figure3 Figure 3 Pharmacokinetic profile of insulin glulisine and regular human insulin in type 1 diabetes mellitus patients after a dose of 0 15 U kg In a study in patients with type 2 diabetes

---

1145130593 jpg

press release CA Nov 3 2008The FDA has approved the fast acting insulin Apidra insulin glulisine for use in children four years and older who have type 1 diabetes Apidra Last updated on Jan 24 2007

---

DisplayImage asp

Figure 3 Pharmacokinetic profile of insulin glulisine and regular human insulin in type 1 diabetes mellitus patients after a dose of 0 15 U kg In a study in patients with type 2

---

DisplayImage asp

Figure 3 Pharmacokinetic profile of insulin glulisine and regular human insulin in type 1 diabetes mellitus patients after a dose of 0 15 U kg In a study in patients with type 2

---